Exosens stock climbs 3.5% and posts best gain in SBF 120

Leading the SBF 120 in a divided European market, Exosens breaks above its three moving averages

Exosens gained 3.31% to €60.85 during the session, while the SBF 120 declined 0.73% and the CAC 40 fell 0.76%. The stock thus topped the broader index, contrasting with a Paris market under pressure amid rising international interest rates (the Bank of Japan raised its rate to 1.25%, its highest since 1995, and the Fed increased its rates on Wednesday). Technical setup supports this momentum: the share price is trading above its three moving averages, at +5.40% above the 20-day MA (€57.73), +2.41% above the 50-day MA (€59.42) and +3.24% above the 200-day MA (€58.94).

The RSI at 53 remains in neutral territory with no overbought signal. Over the week, the stock is up 8.76%, driven primarily by the previous day's jump. The next resistance level stands at €66.80, approximately 9.8% above the current price.

Oddo BHF and Deutsche Bank raise their price targets following annual guidance revision

Two research firms updated their ratings on Exosens on Friday. Oddo BHF raised its price target from €66 to €69 while maintaining an "outperform" rating, representing upside potential of approximately 13% from the current price. Deutsche Bank adjusted its target from €60 to €63 while retaining its "hold" rating, implying more limited upside of roughly 3.5%.

These revisions follow the announcement of new 2026 targets disclosed on September 17, which project approximately 20% revenue growth (up to €570 million) and approximately 25% adjusted EBITDA growth. The divergence between the two views reflects different interpretations of the file: between an outperformance scenario supported by Oddo and a more cautious approach adopted by Deutsche Bank, the next concrete verification point will be the nine-month results publication, expected on October 27.